March 15, 2023
RFP Release Date: March 13, 2023
Estimated Award Date: February 29, 2024
NOT-CA-23-028 - Notice of Proposed Contract Action (Presolicitation) for Request for Proposals (RFP) Solicitation 75N91023R00024: PREVENT Cancer Preclinical Drug Development Program
National Cancer Institute (NCI)
Announcement regarding availability of Request for Proposal (RFP)
RFP or Solicitation https://sam.gov/opp/7a709a40053947df9ad5b3cffe1396bd/view can be found at the sam.gov site. Notice ID: 75N91023R00034. Notice ID: 75N91023R00034
Description:
The National Cancer Institute issued a Request for Proposals (RFP) 75N91023R00034 for the NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT AWARD PROGRAM.
The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas:
- Development of therapeutic technologies for treatment or prevention of
Pediatric Cancers and/or Rare Cancers.
- Development of devices or diagnostic technologies for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers.
For this solicitation rare cancers with a 5-year survival rate of less than 50 % are encouraged and rare cancers would be defined as including all the cancers listed by the NIH Genetics and Rare Diseases Information Center. The list can be found here: https://rarediseases.info.nih.gov/diseases/diseases-by-category/1/rare-cancers. Access the NCI Surveillance, Epidemiology, and End Results Program (SEER) database (https://seer.cancer.gov/) for more information regarding 5-year cancer survival rates.
Preliminary data is not required; however, the ideas should have sound scientific premise either based on the offeror’s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path. Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Awards will also include requirements to enhance entrepreneurship skills and to develop or refine a business model and commercialization plan.
This solicitation is a Concept Award program that could serve as a pipeline for the federal Small Business Innovation Research (SBIR) program. Background for the SBIR program can be found in the Small Business Administration’s policy directive found here: https://www.sbir.gov/sites/default/files/SBA_SBIR_STTR_POLICY_DIRECTIVE_OCT_2020_v2.pdf.
The RFP is anticipated to result in approximately 5-10 awards. NCI will make awards to the offerors based on the following considerations: Technical Evaluation; Areas of high program relevance; Program balance (i.e., balance among areas of research); Availability of funds; and, Cost/Price reasonableness. Awards are anticipated in February 2024. Awards are anticipated to be Firm Fixed Price (FFP). The duration of the contract(s) is anticipated to be twelve (12) months with a budget up to $300,000.
This advertisement does not commit the United States Federal Government to award any contract. The NAICS code for this acquisition is 54171, Research and Development in the Physical, Engineering, and Life Sciences with a size standard of 500 employees.
Place of Performance:
All research or research and development work must be performed by the Small Business Concern (SBC) and any subcontractors in the United States.
Set-Aside Status:
Total Small Business Set-Aside (FAR 19.5)
The RFP Solicitation 75N91023R00034 was released on March 13, 2023 and the deadlines for questions and proposal submission are specified in the RFP and any amendments. The RFP will only be available electronically and must be accessed through SAM.gov https://www.sam.gov/. All information required for submission of a proposal will be contained in the electronic Request for Proposal (RFP) package. No collect calls or facsimile transmissions will be accepted. It is the offerors' responsibility to monitor the above-mentioned sites for release of the solicitation and any amendments. All responsible sources may submit a proposal, which shall be considered by the agency.
POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND ANY AMENDMENTS THAT MAY BE ISSUED. FAILURE TO DO SO WILL BE AT THE OFFEROR’S OWN RISK. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE CONTRACTING OFFICER(S) LISTED AS THE POINT OF CONTACT BELOW.
Contracting Office Address: Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions (OA), Riverside Five, 8490 Progress Drive, Suite 400, Frederick, MD 21701
Randall Tiqui
Office of Acquisitions
National Cancer Institute (NCI)
Email: Randall.Tiqui@nih.gov
and Human Services (HHS)
